Demyelinating Diseases  >>  ozanezumab (GSK 1223249)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ozanezumab (GSK 1223249) / GSK
NCT01424423: NOGO-A in Multiple Sclerosis FTIH

Terminated
1
3
RoW
Placebo, GSK1223249
GlaxoSmithKline
Multiple Sclerosis
08/10
08/10

Download Options